Table 3 Therapeutic studies on blood flow in CADASIL
Drug | Effect |
|---|---|
Acetazolamide | Related to an increase of cerebral perfusion evaluated by perfusion MRI [156], transcranial Doppler sonography [157] and Tc-99 m extracellular domain brain perfusion SPECT [158, 159] |
Atorvastatin | No effects on cerebral blood flow [160], tested with transcranial Doppler |
L-arginine | Induced-vasoreactivity [161], tested with transcranial Doppler |
Sapropterin (200–400 mg bid in 24 months) | Final results for the primary end-point (mean difference in reactive hyperemia index) were not significant for any improvement of peripheral vasoreactivity [162] |
Novel molecular therapeutic target (as stem cell factor and granulocyte-colony stimulating factor) | Ongoing [163] |